Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, with many patients quitting GLP-1 treatment within a year.

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Among a plethora of weight-management plans and dietary charts (namely, keto, dash, sirtfood, paleo or crash diet), climbing ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...